Abstract
Chimeric Antigen Receptor T-cell therapy (CAR-T) stands as a significant breakthrough in the evolving field of immunotherapy. However, due to the lack of well-defined molecular targets in solid tumors, its efficacy has been confined to the treatment of hematological malignancies. The diverse repertoire of B cell receptors (BCR) suggests the presence of a specific B cell subpopulation with…